Navigation Links
Dr. Michael Hanley Joins Celtaxsys as CEO
Date:12/2/2010

ATLANTA, Dec. 2, 2010 /PRNewswire/ -- Georgia -based drug discovery start-up, Celtaxsys, Inc. is pleased to announce that Dr. Michael Hanley has joined the company as its new Chief Executive Officer and Chairman of the Board of Directors.  Dr. Hanley has served on both the Scientific Advisory Board and Board of Directors of Celtaxsys since 2007. Dr. Hanley brings more than 20 years of managerial experience in the international life science industry including drug discovery, product development, and production.  He was most recently the Chief Scientific Officer for Amylin Pharmaceuticals where he was responsible for discovery research and preclinical development.  

"We are very pleased that Dr. Hanley has joined us as CEO," says William Reddick, CFO and Founder of Celtaxsys. "His background as an industry leader, and as an innovative drug hunter, with direct knowledge of our area of research, are qualities well-matched to our needs. We are delighted in the strengths he brings to Celtaxsys."  

"Over the last few years I have gained an insight into the innovative technology and exciting research and development that are at the core of Celtaxsys. I look forward towards building long-term, future success and stakeholder value at the Company," says Michael Hanley.  

From 1981 to 1997, Dr. Hanley held faculty positions at Imperial College, London, the Medical Research Council Laboratories, Cambridge, and the University of California at Davis, where he was Professor of Biological Chemistry. From 1997 to 2003, he was a senior consultant for healthcare investors in the venture capital and banking communities and for biotechnology companies such as Cell Therapeutics, Zymogenetics, Elan Pharmaceuticals, and Chiron. Dr. Hanley has founded several start-ups, such as Resolvyx Pharmaceuticals and Psylin Neurosciences, and is currently on boards of Aileron Therapeutics, Metabolic Solutions Development Company, Isogenica, and Pieris. He received a bachelor's degree in Biochemistry and a Ph.D. in Molecular Biology from the University of California, Berkeley.

About Celtaxsys

Celtaxsys is privately-held start-up focused on discovery and development of therapeutics to treat inflammation. The Company has identified a portfolio of immunoregulators that redirect immune cell migration and activation. Initial product candidates can ameliorate acute and chronic inflammatory disorders of cutaneous, and other, barrier epithelia.

For more information please contact Ralph Grosswald at rgrosswald@celtaxsys.com


'/>"/>
SOURCE Celtaxsys, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. NeuroDerm Awarded $1M by The Michael J. Fox Foundation for the Clinical Development of a New Dermal Patch for Parkinsons Disease
2. Vaccinogen Names Veteran Biotech Executive Michael Kranda President & CEO
3. Michael J. Fox Foundation Launches Parkinsons Progression Markers Initiative (PPMI)
4. Epitomics, Inc. Announces Worldwide Availability of LRRK2 Antibodies Developed in Partnership With The Michael J. Fox Foundation
5. Canadas Michael Smith Genome Sciences Center Validates NEBNext™ DNA Sample Preparation Reagents From New England Biolabs for Use in Next Generation Sequencing
6. Michael Garippa Joins SynCardia as President
7. 2010 Michael E. DeBakey Journalism Awards Announced
8. Michael Youssef Offers Insight into the Muslim Perspective on Oil and the World Economy
9. Oramed Pharmaceuticals Announces That Dr. Michael Berelowitz, Senior Vice President at Pfizer, Joins its Board of Directors
10. Michael Sitaras of SavATree Earns ISA Certified Arborist Designation
11. Michael J. Fox Foundation Offers High-Quality LRRK2 Antibodies for PD Therapeutic Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... Limited (TSX:GEN) ("GeneNews" or the "Company") announced today the ... for breast cancer, via its Virginia -based ... blood-based biomarker test with a sophisticated algorithm to determine a ... ... measures the fasting plasma levels of two biomarkers in the ...
(Date:3/29/2017)... March 29, 2017 The Global Microfluidic Chips ... is a specialized and comprehensive study on the existing state of ... , Europe and Asia-Pacific ... East and Africa . ... Browse 172 Tables and Figures, ...
(Date:3/28/2017)... ... March 28, 2017 , ... NetDimensions announced ... processes and enhance training plan management for consistent implementation of standards and regulatory ... the SHL Group to help improve and streamline their training and employee development ...
(Date:3/28/2017)... ... March 28, 2017 , ... Franz Inc ., the ... AllegroGraph , has been named a ‘Champion’ by Bloor Research in its recent ... product in its class, and, thanks to Gruff, it was rated as the easiest ...
Breaking Biology Technology:
(Date:3/9/2017)... MOUNTAIN VIEW, Calif. , March 9, 2017 ... and 23andMe , the leading personal genetics company, ... Zipongo can now provide customers with personalized nutrition plans ... and biometrics, but also genetic markers impacting how their ... Zipongo,s personalized food decision support platform uses biometrics such ...
(Date:3/7/2017)... , March 7, 2017   HireVue , the ... global companies identify the best talent, faster, today announced ... Sales Officer (CSO) and Diana Kucer as ... out a seasoned executive team poised to drive continued growth ... on a year of record bookings in 2017. ...
(Date:3/2/2017)... Summary This report provides all the information you ... activities since 2010. ... Read the full report: http://www.reportlinker.com/p03605615-summary/view-report.html ... an in-depth insight into the partnering activity of one of ... company reports are prepared upon purchase to ensure inclusion of ...
Breaking Biology News(10 mins):